Sanofi reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent ...

Sanofi (SNY) stock gains as the company posts a Q3 beat for 2025, driven mainly by Dupixent, an asthma therapy it markets ...

Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.

French drug major Sanofi reported a slight dip in third-quarter profit on Friday, even as sales rose, lifted by strong growth ...

Sanofi SA (SNY) reports a 7% revenue increase, with significant contributions from DUPIXENT and new product launches, despite ...

France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its ...

The MoU supports Saudi Vision 2030 and the National Transformation Program’s focus on localizing healthcare manufacturing ...

Sanofi India announces the appointment of Deepak Arora as its Managing Director. Arora will lead strategic initiatives, ...

The new MD will define the company’s India strategy in alignment with Sanofi’s global strategy, besides driving priorities to ...

Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.

In this role, Arora will define and drive the strategic vision for India in alignment with Sanofi's global strategy. He will ...

Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and ...